{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T13:54:00Z","timestamp":1649080440686},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11886-019-1211-z","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T07:02:45Z","timestamp":1567839765000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is There a Safety Concern for Drug-Coated Balloons in Peripheral Arterial Disease?"],"prefix":"10.1007","volume":"21","author":[{"given":"Mohamed M.","family":"Gad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonette K.","family":"Karrthik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad A.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed N.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,7]]},"reference":[{"issue":"4","key":"1211_CR1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","volume":"123","author":"VL Roger","year":"2011","unstructured":"Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18\u2013e209.","journal-title":"Circulation"},{"key":"1211_CR2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","volume":"45 Suppl S","author":"L Norgren","year":"2007","unstructured":"Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5\u201367.","journal-title":"J Vasc Surg"},{"issue":"4","key":"1211_CR3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.amepre.2006.12.010","volume":"32","author":"MA Allison","year":"2007","unstructured":"Allison MA, Ho E, Denenberg JO, Langer RD, Newman AB, Fabsitz RR, et al. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med. 2007;32(4):328\u201333.","journal-title":"Am J Prev Med"},{"issue":"10","key":"1211_CR4","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.amjcard.2018.08.018","volume":"122","author":"R Doshi","year":"2018","unstructured":"Doshi R, Changal KH, Gupta R, Shah J, Patel K, Desai R, et al. Comparison of outcomes and cost of endovascular management versus surgical bypass for the management of lower extremities peripheral arterial disease. Am J Cardiol. 2018;122(10):1790\u20136.","journal-title":"Am J Cardiol"},{"key":"1211_CR5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/B978-0-323-04145-4.50023-5","volume-title":"Levin and O\u2019Neal\u2019s the diabetic foot","author":"H Hoppe","year":"2008","unstructured":"Hoppe H, Kaufman JA. CHAPTER 16 - Radiologic intervention in diabetic peripheral vascular disease. In: Bowker JH, Pfeifer MA, editors. Levin and O\u2019Neal\u2019s the diabetic foot. Seventh ed. Philadelphia: Mosby; 2008. p. 329\u201337.","edition":"Seventh"},{"key":"1211_CR6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/B978-0-323-05726-4.00010-X","volume-title":"Comprehensive vascular and endovascular surgery","author":"BH Gray","year":"2009","unstructured":"Gray BH. Chapter 9b - Endovascular treatment of lower extremity arterial occlusive disease: femoropopliteal and tibial interventions. In: Hallett JW, Mills JL, Earnshaw JJ, Reekers JA, Rooke TW, editors. Comprehensive vascular and endovascular surgery. Second ed. Philadelphia: Mosby; 2009. p. 151\u201375.","edition":"Second"},{"issue":"1","key":"1211_CR7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1148\/radiol.2221010268","volume":"222","author":"HF Lugmayr","year":"2002","unstructured":"Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith A. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow-up. Radiology. 2002;222(1):37\u201343.","journal-title":"Radiology"},{"issue":"18","key":"1211_CR8","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa051303","volume":"354","author":"M Schillinger","year":"2006","unstructured":"Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879\u201388.","journal-title":"N Engl J Med"},{"issue":"2","key":"1211_CR9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1148\/radiol.2322031345","volume":"232","author":"S Sabeti","year":"2004","unstructured":"Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W, Ahmadi R, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis. Radiology. 2004;232(2):516\u201321.","journal-title":"Radiology"},{"issue":"1","key":"1211_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1051-0443(07)61397-9","volume":"12","author":"M Cejna","year":"2001","unstructured":"Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik K, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12(1):23\u201331.","journal-title":"J Vasc Interv Radiol"},{"issue":"8","key":"1211_CR11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1051-0443(07)61572-3","volume":"12","author":"J Grimm","year":"2001","unstructured":"Grimm J, Muller-Hulsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001;12(8):935\u201342.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"1211_CR12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1067\/mva.2003.155","volume":"37","author":"JP Becquemin","year":"2003","unstructured":"Becquemin JP, Favre JP, Marzelle J, Nemoz C, Corsin C, Leizorovicz A. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg. 2003;37(3):487\u201394.","journal-title":"J Vasc Surg"},{"issue":"6","key":"1211_CR13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s002709900186","volume":"20","author":"D Vroegindeweij","year":"1997","unstructured":"Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study. Cardiovasc Intervent Radiol. 1997;20(6):420\u20135.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"1211_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1583\/11-3627.1","volume":"19","author":"JR Laird","year":"2012","unstructured":"Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19(1):1\u20139.","journal-title":"J Endovasc Ther"},{"issue":"21","key":"1211_CR15","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1161\/CIRCULATIONAHA.107.688341","volume":"115","author":"M Schillinger","year":"2007","unstructured":"Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115(21):2745\u20139.","journal-title":"Circulation"},{"issue":"2","key":"1211_CR16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1531003508319778","volume":"20","author":"MR Back","year":"2008","unstructured":"Back MR. Commentary. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Perspect Vasc Surg Endovasc Ther. 2008;20(2):228\u201330.","journal-title":"Perspect Vasc Surg Endovasc Ther"},{"issue":"21","key":"1211_CR17","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1161\/CIRCULATIONAHA.107.730648","volume":"116","author":"M Schillinger","year":"2007","unstructured":"Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Response to letter regarding article, \u201csustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting\u201d. Circulation. 2007;116(21):e546\u2013e.","journal-title":"Circulation"},{"issue":"9","key":"1211_CR18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.5830\/CVJA-2012-019","volume":"23","author":"D Kruger","year":"2012","unstructured":"Kruger D. Neo-intimal hyperplasia, diabetes and endovascular injury. Cardiovasc J Afr. 2012;23(9):507\u201311.","journal-title":"Cardiovasc J Afr"},{"issue":"5","key":"1211_CR19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1583\/11-3560.1","volume":"18","author":"MD Dake","year":"2011","unstructured":"Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011;18(5):613\u201323.","journal-title":"J Endovasc Ther"},{"issue":"4","key":"1211_CR20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/vhrm.2005.1.4.263","volume":"1","author":"T Htay","year":"2005","unstructured":"Htay T, Liu MW. Drug-eluting stent: a review and update. Vasc Health Risk Manag. 2005;1(4):263\u201376.","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"1211_CR21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/CIRCINTERVENTIONS.112.971630","volume":"5","author":"M Werk","year":"2012","unstructured":"Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831\u201340.","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"1211_CR22","first-page":"207","volume":"55","author":"F Fanelli","year":"2014","unstructured":"Fanelli F, Cannavale A, Corona M, Lucatelli P, Wlderk A, Salvatori FM. The \u201cDEBELLUM\u201d--lower limb multilevel treatment with drug eluting balloon--randomized trial: 1-year results. J Cardiovasc Surg. 2014;55(2):207\u201316.","journal-title":"J Cardiovasc Surg"},{"issue":"2","key":"1211_CR23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1406235","volume":"373","author":"K Rosenfield","year":"2015","unstructured":"Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145\u201353.","journal-title":"N Engl J Med"},{"issue":"1","key":"1211_CR24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1526602814564383","volume":"22","author":"D Scheinert","year":"2015","unstructured":"Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22(1):14\u201321.","journal-title":"J Endovasc Ther"},{"issue":"18","key":"1211_CR25","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jcin.2016.06.055","volume":"9","author":"X Jia","year":"2016","unstructured":"Jia X, Zhang J, Zhuang B, Fu W, Wu D, Wang F, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial. JACC Cardiovasc Interv. 2016;9(18):1941\u20139.","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"1211_CR26","doi-asserted-by":"crossref","first-page":"e005891","DOI":"10.1161\/CIRCINTERVENTIONS.117.005891","volume":"11","author":"PA Schneider","year":"2018","unstructured":"Schneider PA, Laird JR, Tepe G, Brodmann M, Zeller T, Scheinert D, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11(1):e005891.","journal-title":"Circ Cardiovasc Interv"},{"issue":"23","key":"1211_CR27","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jcin.2018.08.034","volume":"11","author":"M Brodmann","year":"2018","unstructured":"Brodmann M, Werner M, Meyer DR, Reimer P, Kruger K, Granada JF, et al. Sustainable antirestenosis effect with a low-dose drug-coated balloon: the ILLUMENATE European randomized clinical trial 2-year results. JACC Cardiovasc Interv. 2018;11(23):2357\u201364.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"1211_CR28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1055\/s-0038-1676360","volume":"35","author":"J Lindquist","year":"2018","unstructured":"Lindquist J, Schramm K. Drug-eluting balloons and drug-eluting stents in the treatment of peripheral vascular disease. Semin Interv Radiol. 2018;35(5):443\u201352.","journal-title":"Semin Interv Radiol"},{"issue":"6","key":"1211_CR29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2018.11.039","volume":"73","author":"Y Bausback","year":"2019","unstructured":"Bausback Y, Wittig T, Schmidt A, Zeller T, Bosiers M, Peeters P, et al. Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease. J Am Coll Cardiol. 2019;73(6):667\u201379.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"1211_CR30","doi-asserted-by":"crossref","first-page":"e011245","DOI":"10.1161\/JAHA.118.011245","volume":"7","author":"K Katsanos","year":"2018","unstructured":". Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal srtery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245 Findings from the meta-analysis published by Katsanos et al. suggested an increased mortality risk associated with paclitaxel-coated devices and highlighted the lack of long-term follow-up data.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1211_CR31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13063-017-1968-6","volume":"18","author":"BD Hunt","year":"2017","unstructured":"Hunt BD, Popplewell MA, Davies H, Meecham L, Jarrett H, Bate G, et al. BAlloon versus stenting in severe ischaemia of the Leg-3 (BASIL-3): study protocol for a randomised controlled trial. Trials. 2017;18(1):224.","journal-title":"Trials."},{"key":"1211_CR32","unstructured":"Swedish Drug-elution Trial in Peripheral Arterial Disease (SWEDEPAD) [06\/01\/2019]. Available from: \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02051088\n                      \n                    . Accessed 8 June 2019."},{"key":"1211_CR33","unstructured":"(FDA) USFaDA. Treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality - letter to health care providers 2019 [Available from: \n                      https:\/\/www.fda.gov\/medical-devices\/letters-health-care-providers\/treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel-eluting-stents\n                      \n                    . Accessed 8 June 2019."},{"key":"1211_CR34","unstructured":"(FDA) USFaDA. UPDATE: Treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality - letter to health care providers 2019 [Available from: \n                      https:\/\/www.fda.gov\/medical-devices\/letters-health-care-providers\/update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel-eluting\n                      \n                    . Accessed 8 June 2019."},{"key":"1211_CR35","unstructured":"Granada J. Toxicological aspects and safety profile of paclitaxel [Internet]. \n                      Linc2019.cncptdlx.com\n                      \n                    . 2019 [cited 9 June 2019]. Available from: \n                      https:\/\/linc2019.cncptdlx.com\/media\/1116_Juan_Fernando_Granada_Solis_22_01_2019_Room_1_-_Main_Arena_1_v1.pdf\n                      \n                     [. Accessed 8 June 2019."},{"key":"1211_CR36","unstructured":"Schneider P. DCBs over the long-term: are they safe for our PAD patients? Insights from IN.PACTTM DCB program [Internet]. \n                      Linc2019.cncptdlx.com\n                      \n                    . 2019 [cited 9 June 2019]. Available from: \n                      https:\/\/linc2019.cncptdlx.com\/media\/1128_Peter_Schneider_22_01_2019_Room_1_-_Main_Arena_1.pdf\n                      \n                    . Accessed 8 June 2019."},{"key":"1211_CR37","unstructured":"Dake M. Long-term safety information on paclitaxel eluting stents: insights from the Zilver PTX programme [Internet]. \n                      Linc2019.cncptdlx.com\n                      \n                    . 2019 [cited 9 June 2019]. Available from: \n                      https:\/\/linc2019.cncptdlx.com\/media\/1143_Michael_Dake_22_01_2019_Room_1_-_Main_Arena_1_v2.pdf\n                      \n                     [. Accessed 8 June 2019."},{"key":"1211_CR38","unstructured":"Drug elution in peripheral artery disease (PAD): a critical analysis from a multispecialty consortium [Internet]. 2019 [cited 9 June 2019]. Available from: \n                      https:\/\/vivaphysicians.org\/vlf\n                      \n                    . Accessed 8 June 2019."},{"key":"1211_CR39","unstructured":"SVS announces new task force on paclitaxel safety | Society for Vascular Surgery [Internet]. \n                      Vascular.org\n                      \n                    . 2019 [cited 9 June 2019]. Available from: \n                      https:\/\/vascular.org\/news-advocacy\/svs-announces-new-task-force-paclitaxel-safety\n                      \n                    . Accessed 8 June 2019."},{"key":"1211_CR40","unstructured":"Physician and healthcare payer information | Medtronic [Internet]. \n                      Newsroom.medtronic.com\n                      \n                    . 2019 [cited 9 June 2019]. Available from: \n                      http:\/\/newsroom.medtronic.com\/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=2387744\n                      \n                    . Accessed 8 June 2019."},{"key":"1211_CR41","doi-asserted-by":"publisher","unstructured":"Dake M, Ansel G, Jaff M, Ohki T, Saxon R, Smouse H et al. Correction to: Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery 5-Year Results of the Zilver PTX Randomized Trial. Circulation. 2019;139(8). \n                      https:\/\/doi.org\/10.1161\/CIR.0000000000000657\n                      \n                    .","DOI":"10.1161\/CIR.0000000000000657"},{"issue":"20","key":"1211_CR42","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.jacc.2019.01.013","volume":"73","author":"PA Schneider","year":"2019","unstructured":". Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, et al. Correction mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. Journal of the American College of Cardiology. 2019;73(20):2643 Schneider et al. performed an independent, individual patient-level meta-analysis that showed no statistically significant increase in mortality risk conflicting with prior results reported by Katsanos et al. and igniting further debate about the safety of paclitaxel-coated devices.","journal-title":"Journal of the American College of Cardiology"},{"issue":"15","key":"1211_CR43","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","volume":"133","author":"D Dake Michael","year":"2016","unstructured":"Dake Michael D, Ansel Gary M, Jaff Michael R, Ohki T, Saxon Richard R, Smouse HB, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery. Circulation. 2016;133(15):1472\u201383.","journal-title":"Circulation"},{"issue":"3","key":"1211_CR44","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00270-018-2110-1","volume":"42","author":"K Kichikawa","year":"2019","unstructured":"Kichikawa K, Ichihashi S, Yokoi H, Ohki T, Nakamura M, Komori K, et al. Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 2-year results. Cardiovasc Intervent Radiol. 2019;42(3):358\u201364.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1211_CR45","doi-asserted-by":"crossref","unstructured":"Secemsky EA, Kundi H, Weinberg I, Jaff MR, Krawisz A, Parikh SA, et al. Association of durvival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019.","DOI":"10.1001\/jamacardio.2019.0325"},{"issue":"20","key":"1211_CR46","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1016\/j.jacc.2019.01.013","volume":"73","author":"PA Schneider","year":"2019","unstructured":"Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, et al. Mortality not correlated with paclitaxel exposure. J Am Coll Cardiol. 2019;73(20):2550\u201363.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1211_CR47","first-page":"1368","volume":"44","author":"Eberhard Grube","year":"2004","unstructured":"Grube E, Lansky A, Hauptmann K, Di Mario C, Di Sciascio G, Colombo A et al. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization. J Am Coll Cardiol. 2004;44(7):1368\u201372.","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"1211_CR48","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","volume":"356","author":"Laura Mauri","year":"2007","unstructured":"Mauri L, Hsieh W, Massaro J, Ho K, D'Agostino R, Cutlip D. Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents. N Engl J Med. 2007;356(10):1020\u201329.","journal-title":"New England Journal of Medicine"},{"issue":"9591","key":"1211_CR49","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","volume":"370","author":"Christoph Stettler","year":"2007","unstructured":"Stettler C, Wandel S, Allemann S, Kastrati A, Morice M, Sch\u00f6mig A et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. The Lancet. 2007;370(9591):937\u201348.","journal-title":"The Lancet"},{"issue":"15","key":"1211_CR50","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMoa071167","volume":"357","author":"Daniel F. Hayes","year":"2007","unstructured":"Hayes D, Thor A, Dressler L, Weaver D, Edgerton S, Cowan D et al. HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. N Engl J Med. 2007;357(15):1496\u2013506.","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"1211_CR51","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","volume":"26","author":"EA Perez","year":"2008","unstructured":"Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1211_CR52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.114.011004","volume":"131","author":"G Tepe","year":"2015","unstructured":"Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495\u2013502.","journal-title":"Circulation"},{"issue":"6","key":"1211_CR53","volume":"12","author":"A Laird John","year":"2019","unstructured":"Laird John A, Schneider Peter A, Jaff Michael R, Brodmann M, Zeller T, Metzger DC, et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions. Circ Cardiovasc Interv. 2019;12(6):e007702.","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1211-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1211-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1211-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T00:51:05Z","timestamp":1599353465000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1211-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,7]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1211-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,7]]},"assertion":[{"value":"7 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Mohamed M. Gad, Antonette K. Karrthik, Ahmad A Mahmoud, and Ahmed N. Mahmoud declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"126"}}